Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sellas Life Sciences Group Inc (SLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: SLS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.83
1 Year Target Price $6.83
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 199.01M USD | Price to earnings Ratio - | 1Y Target Price 6.83 |
Price to earnings Ratio - | 1Y Target Price 6.83 | ||
Volume (30-day avg) 3 | Beta 2.54 | 52 Weeks Range 0.77 - 2.27 | Updated Date 09/11/2025 |
52 Weeks Range 0.77 - 2.27 | Updated Date 09/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -68.75% | Return on Equity (TTM) -180.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 173399241 | Price to Sales(TTM) 26.9 |
Enterprise Value 173399241 | Price to Sales(TTM) 26.9 | ||
Enterprise Value to Revenue 20.84 | Enterprise Value to EBITDA -1.71 | Shares Outstanding 105297000 | Shares Floating 104976312 |
Shares Outstanding 105297000 | Shares Floating 104976312 | ||
Percent Insiders 0.32 | Percent Institutions 25.55 |
Upturn AI SWOT
Sellas Life Sciences Group Inc
Company Overview
History and Background
Sellas Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel immunotherapies for cancer. Founded in 2012. Their primary focus is on galinpepimut-S (GPS), a WT1-targeting peptide immunotherapeutic.
Core Business Areas
- Immunotherapy Development: Development of immunotherapies targeting specific cancer antigens to stimulate the patient's immune system to fight cancer cells.
Leadership and Structure
Angelos Stergiou, MD, ScD hc, MBA, is the President and Chief Executive Officer. The company has a board of directors overseeing strategic direction and management team focused on clinical development and commercialization.
Top Products and Market Share
Key Offerings
- Galinpepimut-S (GPS): GPS is a WT1-targeting peptide immunotherapeutic being developed for various cancers, including acute myeloid leukemia (AML) and multiple myeloma (MM). There is currently no market share available. The market is very competitive with large pharmaceutical companies and smaller biotechs developing various cancer therapies. Key competitors include companies with AML therapies, such as Novartis and Bristol Myers Squibb
Market Dynamics
Industry Overview
The immunotherapy market is experiencing significant growth, driven by advances in understanding the immune system's role in cancer and the development of novel therapeutic approaches. The market is competitive and evolving.
Positioning
Sellas positions itself as a leader in WT1-targeted immunotherapy, focusing on developing GPS for cancers with high unmet needs. Their advantage lies in their specific target and potentially differentiated approach.
Total Addressable Market (TAM)
The global cancer immunotherapy market is expected to reach hundreds of billions of dollars. Sellas' positioning with GPS focuses on acute myeloid leukemia (AML) and multiple myeloma (MM), both substantial markets. Their success depends on the clinical trial outcomes and commercialization strategies. The total addressable market for AML and MM in the US is estimated in the billions of dollars.
Upturn SWOT Analysis
Strengths
- Novel WT1-targeting immunotherapy platform
- Experienced management team
- Focus on high unmet medical needs
- Late-stage clinical development
Weaknesses
- Limited financial resources
- Single lead product candidate
- High clinical trial risk
- Reliance on successful clinical trial outcomes
Opportunities
- Potential to expand GPS to other cancer indications
- Partnerships and collaborations for development and commercialization
- Positive clinical trial results
- Regulatory approvals
Threats
- Competition from other immunotherapy approaches
- Clinical trial failures
- Regulatory hurdles
- Market access challenges
- Funding challenges
Competitors and Market Share
Key Competitors
- BMY
- NVS
- MRNA
Competitive Landscape
Sellas faces competition from established pharmaceutical companies and other biotech firms developing immunotherapies. Their success depends on the differentiation and efficacy of GPS. Many players are competing to become the market leader.
Growth Trajectory and Initiatives
Historical Growth: The company's growth depends on the progression of GPS through clinical trials.
Future Projections: Future growth is tied to regulatory approvals and commercialization. Analyst projections are contingent on these factors.
Recent Initiatives: Focus on advancing GPS in AML and MM through clinical trials. Exploring partnership opportunities.
Summary
Sellas Life Sciences is a clinical-stage biopharmaceutical company focused on immunotherapies. The company's success hinges on the successful clinical development and regulatory approval of Galinpepimut-S (GPS). Financial stability and partnerships are crucial for sustained growth. The company faces challenges of clinical trial risks and competition. Positive trial results would provide a significant upswing for the stock and the company as a whole.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sellas Life Sciences Group Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2017-12-29 | Founder, President, CEO & Director Dr. Angelos M. Stergiou M.D., ScD h.c. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | |
Full time employees 15 | |||
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.